Cidara Therapeutics Stock Debt To Equity
| CDTX Stock | USD 20.40 2.95 16.91% |
Cidara Therapeutics fundamentals help investors to digest information that contributes to Cidara Therapeutics' financial success or failures. It also enables traders to predict the movement of Cidara Stock. The fundamental analysis module provides a way to measure Cidara Therapeutics' intrinsic value by examining its available economic and financial indicators, including the cash flow records, the balance sheet account changes, the income statement patterns, and various microeconomic indicators and financial ratios related to Cidara Therapeutics stock.
| Last Reported | Projected for Next Year | ||
| Debt To Equity | (0.16) | (0.14) |
Cidara | Debt To Equity |
Cidara Therapeutics Company Debt To Equity Analysis
Cidara Therapeutics' Debt to Equity is calculated by dividing the Total Debt of a company by its Equity. If the debt exceeds equity of a company, then the creditors have more stakes in a firm than the stockholders. In other words, Debt to Equity ratio provides analysts with insights about composition of both equity and debt, and its influence on the valuation of the company.
Current Cidara Therapeutics Debt To Equity | 0.18 % |
Most of Cidara Therapeutics' fundamental indicators, such as Debt To Equity, are part of a valuation analysis module that helps investors searching for stocks that are currently trading at higher or lower prices than their real value. If the real value is higher than the market price, Cidara Therapeutics is considered to be undervalued, and we provide a buy recommendation. Otherwise, we render a sell signal.
Cidara Debt To Equity Driver Correlations
Understanding the fundamental principles of building solid financial models for Cidara Therapeutics is extremely important. It helps to project a fair market value of Cidara Stock properly, considering its historical fundamentals such as Debt To Equity. Since Cidara Therapeutics' main accounts across its financial reports are all linked and dependent on each other, it is essential to analyze all possible correlations between related accounts. However, instead of reviewing all of Cidara Therapeutics' historical financial statements, investors can examine the correlated drivers to determine its overall health. This can be effectively done using a conventional correlation matrix of Cidara Therapeutics' interrelated accounts and indicators.
Click cells to compare fundamentals
High Debt to Equity ratio typically indicates that a firm has been borrowing aggressively to finance its growth and as a result may experience a burden of additional interest expense. This may reduce earnings or future growth. On the other hand a small D/E ratio may indicate that a company is not taking enough advantage from financial leverage. Debt to Equity ratio measures how the company is leveraging borrowing against the capital invested by the owners.
| Competition |
Cidara Total Stockholder Equity
Total Stockholder Equity |
|
According to the company disclosure, Cidara Therapeutics has a Debt To Equity of 0.178%. This is 99.67% lower than that of the Biotechnology sector and 99.08% lower than that of the Health Care industry. The debt to equity for all United States stocks is 99.63% higher than that of the company.
Cidara Debt To Equity Peer Comparison
Stock peer comparison is one of the most widely used and accepted methods of equity analyses. It analyses Cidara Therapeutics' direct or indirect competition against its Debt To Equity to detect undervalued stocks with similar characteristics or determine the stocks which would be a good addition to a portfolio. Peer analysis of Cidara Therapeutics could also be used in its relative valuation, which is a method of valuing Cidara Therapeutics by comparing valuation metrics of similar companies.Cidara Therapeutics is currently under evaluation in debt to equity category among its peers.
Cidara Therapeutics ESG Sustainability
Some studies have found that companies with high sustainability scores are getting higher valuations than competitors with lower social-engagement activities. While most ESG disclosures are voluntary and do not directly affect the long term financial condition, Cidara Therapeutics' sustainability indicators can be used to identify proper investment strategies using environmental, social, and governance scores that are crucial to Cidara Therapeutics' managers, analysts, and investors.Environmental | Governance | Social |
Cidara Fundamentals
| Return On Equity | -1.53 | ||||
| Return On Asset | -0.16 | ||||
| Profit Margin | (2.11) % | ||||
| Operating Margin | (36.76) % | ||||
| Current Valuation | 20.31 M | ||||
| Shares Outstanding | 7.05 M | ||||
| Shares Owned By Insiders | 4.70 % | ||||
| Shares Owned By Institutions | 51.86 % | ||||
| Number Of Shares Shorted | 64.58 K | ||||
| Price To Earning | (2.21) X | ||||
| Price To Book | 1.24 X | ||||
| Price To Sales | 2.67 X | ||||
| Revenue | 63.91 M | ||||
| Gross Profit | (11.23 M) | ||||
| EBITDA | (24.36 M) | ||||
| Net Income | (22.93 M) | ||||
| Cash And Equivalents | 53.08 M | ||||
| Cash Per Share | 0.74 X | ||||
| Total Debt | 4.88 M | ||||
| Debt To Equity | 0.18 % | ||||
| Current Ratio | 1.93 X | ||||
| Book Value Per Share | (1.81) X | ||||
| Cash Flow From Operations | (22.43 M) | ||||
| Short Ratio | 3.88 X | ||||
| Earnings Per Share | (23.90) X | ||||
| Target Price | 27.33 | ||||
| Number Of Employees | 69 | ||||
| Beta | 0.99 | ||||
| Market Capitalization | 143.75 M | ||||
| Total Asset | 67.03 M | ||||
| Retained Earnings | (441.43 M) | ||||
| Working Capital | (6.56 M) | ||||
| Current Asset | 108.22 M | ||||
| Current Liabilities | 5.97 M | ||||
| Net Asset | 67.03 M |
About Cidara Therapeutics Fundamental Analysis
The Macroaxis Fundamental Analysis modules help investors analyze Cidara Therapeutics's financials across various querterly and yearly statements, indicators and fundamental ratios. We help investors to determine the real value of Cidara Therapeutics using virtually all public information available. We use both quantitative as well as qualitative analysis to arrive at the intrinsic value of Cidara Therapeutics based on its fundamental data. In general, a quantitative approach, as applied to this company, focuses on analyzing financial statements comparatively, whereas a qaualitative method uses data that is important to a company's growth but cannot be measured and presented in a numerical way.
Please read more on our fundamental analysis page.
Also Currently Popular
Analyzing currently trending equities could be an opportunity to develop a better portfolio based on different market momentums that they can trigger. Utilizing the top trending stocks is also useful when creating a market-neutral strategy or pair trading technique involving a short or a long position in a currently trending equity.Additional Tools for Cidara Stock Analysis
When running Cidara Therapeutics' price analysis, check to measure Cidara Therapeutics' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Cidara Therapeutics is operating at the current time. Most of Cidara Therapeutics' value examination focuses on studying past and present price action to predict the probability of Cidara Therapeutics' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Cidara Therapeutics' price. Additionally, you may evaluate how the addition of Cidara Therapeutics to your portfolios can decrease your overall portfolio volatility.